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Abstract: We report the formulation of novel composite nanoparticles that combine the high 
transfection efficiency of cationic peptide-DNA nanoparticles with the biocompatibility and pro-
longed delivery of polylactic acid–polyethylene glycol (PLA-PEG). The cationic cell-penetrating 
peptide RALA was used to condense DNA into nanoparticles that were encapsulated within 
a range of PLA-PEG copolymers. The composite nanoparticles produced exhibited excellent 
physicochemical properties including size ?200 nm and encapsulation efficiency ?80%. Images 
of the composite nanoparticles obtained with a new transmission electron microscopy staining 
method revealed the peptide-DNA nanoparticles within the PLA-PEG matrix. Varying the copo-
lymers modulated the DNA release rate ?6 weeks in vitro. The best formulation was selected 
and was able to transfect cells while maintaining viability. The effect of transferrin-appended 
composite nanoparticles was also studied. Thus, we have demonstrated the manufacture of 
composite nanoparticles for the controlled delivery of DNA.
Keywords: PLA-PEG, cationic peptide, gene delivery, composite nanoparticles, DNA, 
transfection
Introduction
Gene therapy involves the introduction of genes, commonly in the form of DNA or 
RNA, into a cell either to rectify a missing or defective gene or to express a protein 
of therapeutic interest. The use of DNA for gene therapy is a challenge because of its 
inability to cross the cell membrane barrier in its native solution form and its instabil-
ity in the extracellular matrix. Application of a suitable delivery vector can compact 
the DNA providing stability as well as efficient translocation inside the cell through 
attachment to the target cells, cell membrane passage, escape from the endolysosome 
to reach into the cytosol, and, if possible, transport to the nucleus for the expression 
of the desired protein.1,2 Numerous viral and nonviral carriers have shown in vitro 
efficacy, including cationic nanoparticles.3–5 But their major limitation is their high 
toxicity, nonspecificity, and short life span in the blood circulation.1,6–8
PEGylation of particles increases their blood circulation half-life9 leading to 
enhanced bioavailability, also helping them to cross physical and physiological 
barriers.10,11 Polylactic acid–polyethylene glycol (PLA-PEG) nanoparticles have 
been widely used for the safe and prolonged delivery of therapeutics owing to their 
versatile and defined degradation profile that can be customized according to their 
molecular composition and chain lengths. When the block copolymer PLA-PEG 
is formulated into nanoparticles, PLA forms the hydrophobic core and the PEG 
chains form a corona around the nanoparticles giving a brush-like topography,12,13 
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and the degradation profile of the PLA defines the rate of 
drug delivery, while PEG determines the biological fate of 
the particles.
In this paper, composite nanoparticles were developed 
to exploit the advantages of both cationic cell-penetrating 
peptides and PLA-PEG nanoparticles. Cell-penetrating 
peptides have emerged as a specialized tool for the efficient 
intracellular delivery of the therapeutic cargo.14 For gene 
delivery, cell-penetrating peptides that include positively 
charged amphiphilic peptides ?30 amino acid in length15 
exhibit enhanced cell compatibility when compared with 
other available options.16–18 The cationic cell-penetrating 
peptide RALA19 was chosen to condense the DNA and 
form the core of the nanoparticles for efficient transfection 
of the cells. RALA exhibits an alpha helical structure in a 
hydrophilic environment with hydrophobic amino acids on 
one face and hydrophilic on the other, making it a suitable 
candidate for DNA condensation and efficient membrane 
perturbation. The sequence and predicted secondary structure 
of the peptide were generated using PEPstr server,20 and 
the surface was generated using UCSF chimera (Version 1.9) 
software (Figure 1).21
We have found that DNA condensed with RALA to form 
cationic RALA nanoparticles (RNPs) can be encapsulated 
into PLA-PEG nanoparticles to form a composite DNA:RNP 
termed here as “polymeric–cationic peptide composite 
nanoparticles”. This enables the possibility of prolonging 
the rate of DNA release along with the potential for surface 
modification for its targeted delivery. The electrostatic 
interaction between the DNA and cationic peptide was opti-
mized to achieve a cationic nanoparticle formulation close to 
monodispersity in order to allow their encapsulation within 
the PLA-PEG nanoparticles. A series of PLA-PEG poly-
mers were synthesized to evaluate the optimum copolymer 
composition for the encapsulation of RNPs and controlled 
and safe delivery of the DNA. On the basis of their use in 
various biological applications, two PEG chain lengths, 2 and 
5 kDa, were selected and various PLA chain lengths were 
polymerized with them.22–25 Thus, this paper describes the 
manufacture of a composite nanoparticulate system to offer 
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Figure 1 Sequence and structure of RALA. Overview of composition of the composite nanoparticles.
Notes: (A) Primary sequence (top), secondary structure (middle), and surface representations of the RALA peptide, bottom left shows rotation to reveal the hydrophobic 
side, bottom right shows rotation to reveal the hydrophilic side. (B) Schematic representation of polymeric–cationic peptide composite nanoparticles.
Abbreviations: pDNA, plasmid DNA; PEG, polyethylene glycol; PLA, polylactic acid; RNPs, RALA nanoparticles.
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the advantages of PLA-PEG copolymer in terms of safe, 
controlled, and targeted delivery26,27 in combination with the 
high encapsulation and transfection efficiency of the DNA 
payload offered by cationic RNPs.19
Experimental section
Materials
The RALA peptide was purchased from Biomatik, USA. The 
reporter plasmid pEGFP-N1 was purchased from Clontech 
(USA), cloned in DHF5-? (Thermo Fisher Scientific, 
Waltham, MA, USA), and purified using a Maxi-prep 
PureLink™ HiPure Plasmid Purification Kit (Thermo Fisher 
Scientific). For the formulation of RNPs, DNAase/RNAase-
free distilled water (USP water for injection) purchased from 
Thermo Fisher Scientific was used; for all other applications, 
HPLC ultrapure Type 1 (ASTM, CAP, NCCLS standards) 
water processed by PURELAB Prima and PURELAB 
Maxima HPLC (ELGA LabWater) was used. D,L-Lactide 
(3,6-dimethyl-1,4-dioaxane-2,5-dione), polyethylene glycol 
methyl ether (mPEG 2,000/5,000), stannous octoate (Tin(II) 
2-ethylhexanoate, ?95%), chloroform-d (100%, 0.03% TMS 
as standard) PVA (polyvinyl alcohol, average Mw 30,000–
70,000, degree of hydrolysis 87–90%), Ethidium bromide 
(EtBr), proteinase K (BioUltra, ?30 units/mg protein), were 
purchased from Sigma-Aldrich Co. ?,?-Trehalose dehy-
drate (high purity, endotoxin free) was procured from Ferro 
Pfanstiehl Laboratories Inc., USA. Roswell Park Memorial 
Institute (RPMI) 1640, 2.5% Trypsin (10?), 1 kb plus DNA 
ladder, and Quant-iT™ PicoGreen® ds DNA assay kit were 
purchased from Thermo Fisher Scientifc. Fetal calf serum 
was purchased from PAA, Austria. WST-1 cell proliferation 
reagent was bought from Roche Diagnostics Ltd, UK.
Cationic RNPs preparation
RNPs were formed by electrostatic interaction between the 
cationic RALA peptide and the negatively charged phosphate 
backbone of the DNA.19 The charge ratio of the components 
was calculated as N:P ratio, which is the molar ratio of the 
amine groups in the RALA to the phosphates in the DNA. 
RNPs were prepared at various N:P ratios to investigate and 
optimize the condensation behavior. One microgram of DNA 
was mixed with a calculated amount of RALA peptide and 
incubated at room temperature for 20 minutes before further 
experimentation. For the preparation of composite nanopar-
ticles, RNPs in higher DNA concentration were prepared in 
50 mM MOPS buffer at 50?C.
Gel retardation assay was performed by electrophoresis 
through a 0.8% agarose gel containing EtBr with Tris acetate-
ethylenediaminetetraacetic acid running buffer at 80 V for 
1 hour. Gels were imaged using a Biochemi® Multispectrum 
imaging system (UVP, UK). Images are representative of a 
minimum of three independent studies.
PLA-PEG copolymer synthesis and 
characterization
Copolymers were synthesized by the ring opening polym-
erization of D,L-lactide in the presence of prepolymerized 
mPEG 2,000/5,000 (monomethyl ether of polyethylene 
glycol) using stannous octoate as a catalyst.28 Reactants and 
catalyst solutions were azeotropically distilled independently 
before carrying out the polymerization reaction. The crude 
product was obtained by removing toluene and was dissolved 
in dichloromethane (DCM) to precipitate, twice, by cold 
ethyl ether (?80?C) for the purification of the product. The 
purified copolymers were then dried overnight in a vacuum 
desiccator. 1H-NMR spectroscopy was performed to assess 
the ratio of PLA and PEG chain lengths (LA/EG) in the syn-
thesized block copolymers using a Bruker Ultrashield 400 
plus instrument. The LA/EG ratio was calculated using the 
integration value of the peaks corresponding to methine pro-
tons (–CH) of the lactide at ? 5.1 ppm and methylene protons 
(–CH2) of PEG at ? 3.7 ppm.28 Molecular weight and poly-
dispersity index (PDI) of the synthesized copolymers were 
determined by gel permeation chromatography (GPC) using 
Varian/Polymer Laboratories GPC-50 instrument equipped 
with refractive index detector. For molecular weight deter-
mination, chloroform was the mobile phase (40?C and flow 
rate of 1 mL/min). Polymers were dissolved in chloroform, 
filtered, and then injected into a column of 3 ?m Resipore 
Mixed-B, 300 cm ?7.5 cm (Agilent Technologies, Santa 
Clara, CA, USA). Average molecular weights were calcu-
lated using a series of polystyrene standards. Products are 
abbreviated to PLAx-PEGy, where x and y represent the 
molecular weight of the respective block in kilodaltons.
Thermal analysis of the copolymers and 
the composite nanoparticles
Modulated temperature differential scanning calorimetry was 
performed using a QA 100 (TA Instruments, Newcastle, DE, 
USA) calibrated for temperature, enthalpy, and heat capacity. 
Samples in hermetically sealed aluminum pans were heated 
at 3?C/min from ?20?C to 150?C with modulation of ?1?C 
for ?60 seconds using a heat–cool–heat method to remove 
the effect of the accompanying relaxation endotherm from 
the glass transition (Tg). Values were determined from the 
midpoint of the signal step change in the reversing heat 
flow and shown as a “?” sign in the figures. Measurements 
were made in triplicate from three independently prepared 
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formulations, and results are presented as mean ? standard 
deviation (SD).
Formulation of composite nanoparticles 
by double emulsion solvent evaporation 
method
Composite nanoparticles were made with various PLA-
PEG copolymers using a modified double emulsion solvent 
evaporation method.28 Briefly, an aqueous RNP suspension 
was added to 4% w/v copolymeric solution in DCM (1:5 v/v) 
under vortex and probe sonicated (120 Sonic Dismembrator 
with 3 mm probe; Thermo Fisher Scientific) for 60 seconds. 
The water-in-oil (w/o) emulsion was added to 5% w/v 
polyvinyl alcohol solution in distilled water (1:5 v/v) under 
vortex and sonicated again. The resultant w/o/w emulsion 
was stirred overnight to evaporate the organic phase. The 
composite nanoparticles were collected by centrifugation 
at 30,000? g for 30 minutes (3K30; Sigma Centrifuge, UK) 
and washed twice with distilled water before re-suspending 
in 5% w/v aqueous trehalose solution and freeze-dried 
(Advantage, VirTis, Gardiner, NY, USA) using a protocol 
modified from Jain et al.29
To investigate the effect of surface modification on 
transfection efficiency, Tf-appended composite nanoparticles 
were also prepared. Transferrin was adsorbed on the surface 
of nanoparticles using modifications of reported methods30,31 
suspending the nanoparticles in 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid buffer, pH 7.4, with 150 mM 
NaCl containing transferrin. The resultant nanoparticles were 
collected by centrifugation at 25,000? g for 30 minutes.
Further nanoparticle characterization
Particle size and zeta potential values were determined by 
dynamic light scattering using a Malvern zetasizer (Nano 
ZS; Malvern Instruments, Malvern, UK). Freeze-dried 
composite nanoparticles were re-suspended in distilled water 
before analysis. For size determination, the average of five 
readings (at least ten runs each) was taken of each sample; 
data are presented as mean ? SD (n?10) of ten samples from 
different batches.
DNA was quantified using a proteinase K-assisted 
PicoGreen assay according to our previously developed 
protocol.32 Calibration plots were prepared in the range of 
50–1,000 ng/mL for both DNA and RNPs (having equivalent 
DNA concentrations) in Tris buffer (pH 8.0, 20 mM).
Transmission electron microscopy was performed (JEOL 
JEM1400 transmission electron microscope at an accelerat-
ing voltage of 80 kV) to image the RNPs within the composite 
nanoparticles. Composite nanoparticles were prepared with 
the addition of 0.1% w/v osmium tetroxide in the polymer 
containing organic phase to generate the contrast between 
the RNPs and the outer polymer matrix of the composite 
nanoparticles. Samples were loaded over the copper grid 
(Formvar/Carbon 200 mesh, Agar Scientific) by putting a 
drop of sample onto a wax sheet then covering with the grid 
for 1 hour. Excess water was removed from the grid with 
tissue paper before air-drying overnight. For RNPs, the grids 
were negatively stained with 4% ammonium molybdate.
In-process stability study
In-process stability studies were performed to determine 
the effect of probe sonication, DCM, and emulsification on 
the RNPs and condensed plasmid DNA (pDNA) during the 
preparation of composite nanoparticles. To investigate the 
effect of sonication, samples were sonicated at amplitudes of 
40%, 50%, and 60% for durations of 30, 60, and 120 seconds. 
As a control, the pDNA alone was sonicated at the lowest 
amplitude setting (40%) for 30 seconds. Samples were 
loaded onto an agarose gel with and without digestion with 
proteinase K. To investigate the effect of DCM, RNPs were 
vortexed with DCM for different time intervals. To investi-
gate the effect of emulsification, the double emulsion solvent 
evaporation method was performed without the addition of 
polymer to the organic phase, thus removing the requirement 
of the polymeric nanoparticle disruption step. Samples were 
collected after 1 and 2 minutes sonication of the secondary 
emulsion and then loaded onto a gel with and without pro-
teinase K digestion.
In vitro release study
Freeze-dried powders were re-suspended in 1 mL of Tris 
acetate-ethylenediaminetetraacetic acid buffer (40 mM, pH 
adjusted to 7.2 with HCl) with 0.02% sodium azide and 
centrifuged to quantify the RNP concentration in the super-
natants, which corresponds to the amount of free or surface 
adsorbed RNPs present in the composite nanoparticles. The 
composite nanoparticles were re-suspended and incubated at 
37?C in a shaking incubator to perform the in vitro release 
study ?6 weeks. At each time point, the composite nano-
particles were centrifuged to collect the supernatant and 
re-suspended with the fresh buffer. DNA quantification was 
as described earlier.
Cell culture studies
Cell culture studies were performed using ZR-75-1 breast 
cancer cells from the American Tissue Culture Collection 
maintained in RPMI 1640 medium supplemented with 10% 
fetal calf serum. ZR-75-1 cells were seeded at a density of 
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1?105 cells/well onto 24-well tissue culture plates (VWR, 
UK) for 24 hours prior to transfection. Cells were conditioned 
for 2 hours in Opti-MEM (Thermo Fisher Scientific), which 
was then supplemented with either RNPs or composite 
nanoparticles. Following incubation for 6 hours (RNPs) or 
24 hours (with composite nanoparticles), the media were 
removed and replaced with the serum-supplemented cul-
ture media and further incubated for 24 hours. Transfection 
efficiency was qualitatively evaluated using an inverted 
fluorescence microscope (Nikon Eclipse TE300; Nikon 
Instruments, Melville, NY, USA) with an epifluorescence 
source (Nikon Instruments). Images were captured using 
a DXM1200 (Nikon Instruments) digital camera at ?100 
magnification. After imaging, cells were harvested and 
transfection efficiency was quantitatively measured using 
flow cytometry (FACSCalibur system; BD Biosciences, 
San Jose, CA, USA). The data were analyzed using Cyflogic 
software (Version 1.2.1; CyFlo, Ltd., Turku, Finland), and 
percent fluorescent cell values were reported as 4% gating 
of the controlled untreated cells.
Cell viability after treatment with nanoparticles was deter-
mined by washing the cells with phosphate-buffered saline 
followed by addition of 100 ?L of 10% WST-1 reagent in 
serum-free media and incubation in standard CO2 incubator 
for 2 hours. The plate was read (EL808 plate-reader; Biotek, 
USA), and values are presented as percentage compared to 
untreated cells as a positive control.
Statistical analysis
Statistical analysis was performed using GraphPad prism 
6 and GraphPad InStat 3 (GraphPad Software, Inc., La 
Jolla, CA, USA). One-way analysis of variance followed 
by Dunnett’s post hoc test was used to compare the data set 
(more than three groups). A P-value ?0.05 was considered 
to indicate statistical significance for comparison. All data 
are presented as mean ? SD of three independently performed 
repeats unless otherwise specified.
Results and discussion
Formulation of cationic peptide-DNA 
nanoparticles (RNPs)
Figure 2A shows a representative image of the gel retarda-
tion assay performed to determine the N:P ratio required 
to condense DNA into the RNPs. Lanes corresponding to 
nanoparticles prepared with N:P ratios of 0.5–2.5 exhibit 
a DNA band at the same distance as pDNA (labeled D), 
indicating that in these formulations, the amount of RALA 
peptide was not sufficient to condense the DNA completely. 
At N:P ratio ?3, no migration of DNA into the gel was seen 
indicating that beyond this ratio the DNA was condensed 
with the peptide. Lanes corresponding to N:P ratios of 3–4 
showed some fluorescence in the well indicating formation 
of DNA-peptide aggregates, while at higher N:P ratios no 
DNA fluorescence was seen, confirming that in these lanes, 
the DNA is buried within the RNPs.
These findings indicate that the condensation of pDNA 
by RALA peptide progresses in a similar manner to that 
described previously for multivalent cations; this sponta-
neous collapse of DNA is defined as condensation33,34 and 
explained by an all-or-none transition phenomenon.35–37 
At low concentrations, RALA disrupts the supercoiled 
structure of the pDNA, but beyond the critical condensing 
concentration (NP ?2), it causes the collapse of the DNA 
and forms nanoparticles (Figure 2B). These observations 
are in-line with the explanation provided by Porschke,38 
where they found that spermine (a tetravalent cation) forms 
a sheath around DNA until its concentration is raised to a 
threshold concentration enabling condensation of the DNA. 
We also observed that the zeta potential increased with N:P 
ratio and exhibited a sudden charge inversion at N:P ratio 
of 2 (Figure 2C). This effect and net positive charge on the 
surface of the nanoparticles even after the complete neu-
tralization of DNA molecule can be explained by the “tails 
and arches” theory.39,40 Further, the zeta potential remained 
consistently ?20 mV for the formulations prepared with 
N:P ratio ?4 indicating the complete condensation of DNA, 
while the particle diameter was in the sub-100 nm range at 
N:P ratios ?6. On the basis of these findings, a N:P ratio of 
10 was considered to be optimum for the efficient production 
of RNPs and used for further studies; the Z-average diameter 
of ten independently prepared batches was determined to 
be 70.6?7.5 nm with a PDI of 0.240?0.054. Preparation 
of the composite nanoparticles required RNPs at a higher 
concentration where these conditions failed to control the 
condensation giving rise to polydispersed nanoparticles 
with a bimodal size distribution. After further optimizing 
the pH and thermodynamic conditions for the controlled 
condensation, these high concentration RNPs were prepared 
in 50 mM MOPS buffer at 50?C (optimization data are not 
shown). The Z-average particle size of the nanoparticles 
produced under these conditions was 55.2?10.6 nm with a 
PDI of 0.232?0.050 (n?16).
Characterization of the PLA-PEG 
copolymers
NMR indicated that the calculated chain length ratio of the 
synthesized polymers was close to the desired chain length 
ratio (Table 1) and GPC showed monomodal distribution 
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curves with no peaks corresponding to the molecular 
weights of the reactants. The polydispersity values (Mw/Mn) 
of the synthesized copolymers were in the range 1.2–1.4 
indicating their suitability for the manufacture of composite 
nanoparticles.
Thermal properties of the polymers
Melting points (Tfus) values for copolymers containing PEG 
2000 were lower than those containing PEG 5000 because 
of the higher Tfus value of PEG 5000. Increasing the PEG 
content lowered the Tg and increased the heat of fusion (?fusH) 
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Figure 2 Formulation optimization of RNPs.
Notes: (A and B) Gel retardation assay. Numbers denote the N:P ratio. (C) Particle size analysis and zeta potential of RNPs made at different N:P ratios. Error bars show ?SD, n?3.
Abbreviations: L, 1 kb plus DNA ladder; N, native pDNA; OC, open circular/relaxed plasmid DNA; SC, supercoiled plasmid DNA; RNPs, RALA nanoparticles; 
pDNA, plasmid DNA; SD, standard deviation; PDI, polydispersity index.
Table 1 Size and thermal properties of the synthesized PLA-PEG copolymers
Polymera Theoretical  
LA/EG ratio
1H-NMR spectroscopy Gel permeation 
chromatography
%PEG 
(mol%)
Tg (?C) Tfus (?C) ?fusH (J/g)
LA/EG ratio Mn Mw Mn Mw/Mn
PLA10-PEG2 5 4.54 11,080 16,427 13,071 1.25 11.0 13.5?0.9 39.6?1.2 27.6?0.1
PLA20-PEG2 10 12.3 26,600 26,028 18,160 1.40 4.58 37.5?0.7 38.4?1.1 7.68?0.8
PLA10-PEG5 2 1.52 12,600 10,706 9,518 1.06 24.2 – 47.0?0.1 69.6?2.4
PLA25-PEG5 5 4.36 26,800 29,666 23,186 1.28 11.3 18.2?1.1 49.9?1.3 34.9?2.8
PLA50-PEG5 10 11.1 60,500 44,986 33,290 1.35 5.06 25.7?1.2 43.8?0.1 16.5?1.5
Notes: aSubscript shows molecular weight in kilodaltons. Mn, number average molecular weight; Mw, weight average molecular weight; Mw/Mn, polydispersity index of the polymer.
Abbreviations: PLA, polylactic acid; PEG, polyethylene glycol; 1H-NMR, proton nuclear magnetic resonance;Tg, glass transition temperature; Tfus, melting points; ?fusH, heat 
of fusion.
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of the copolymers (Table 1; Figure S1). For example, the 
copolymers PLA20-PEG2 and PLA25-PEG5 have similar PLA 
chain lengths, but the latter has a higher PEG content that 
leads to its higher ?fusH and lower Tg, whereas PLA10-PEG2 
and PLA25-PEG5 exhibited closer values for ?fusH and lower 
Tg because of their similar %PEG contents irrespective of the 
higher PLA and PEG chain lengths of PLA25-PEG5. These 
results indicate that the total PEG content has the largest influ-
ence on the thermal properties of the bulk copolymers.
Formulation of composite nanoparticles
Composite nanoparticles were prepared using the modified 
double emulsion solvent evaporation method with optimi-
zation for the synthesis of copolymeric nanoparticles as 
follows.
Optimization of DNA/polymer ratio
The formulation method was optimized for RNP content by 
adjusting the DNA/polymer ratio (?g/mg) using PLA25-PEG5 
copolymer in the range of 0–1.0 ?g/mg (Figure S2). Particle 
size and zeta potential of the copolymer nanoparticles were 
not affected by loading with the RNPs. Similarly, constant zeta 
potential values were observed across the range of loadings 
studied, indicating that in all cases, the RNPs were incorpo-
rated within the core of the composite nanoparticles and that 
the surface charge was solely determined by the copolymer. 
A small but statistically insignificant decrease in the particle 
size was observed in composite nanoparticles compared to 
empty polymeric nanoparticles (Figure S2). This size decrease 
might be attributed to the charge–charge interaction between 
the cationic RNPs and the negative charge of the polymer 
chains. The composite nanoparticles prepared with 0.25 ?g/mg 
DNA/polymer ratio were selected for use in further studies.
Characterization of composite 
nanoparticles
Composite nanoparticles were characterized for their size, 
size distribution, surface charge, and encapsulation effi-
ciency (Table 2). The smallest nanoparticles were formed by 
PLA10-PEG2 and PLA10-PEG5 with particle size of 145 nm that 
was attributed to their low molecular weight. The yields of 
these nanoparticles were very low; furthermore, the nanopar-
ticles made with PLA10-PEG5 exhibited a low encapsulation 
efficiency indicating that they failed to form a stable emul-
sion during preparation. These nanoparticles were therefore 
considered unsuitable for further characterization. Increasing 
the PLA molecular weight increased the particle size, for 
example, PLA20-PEG2 ? PLA10-PEG2 (P?0.001) and PLA25-
PEG5 ? PLA10-PEG5 (P?0.001). PLA50-PEG5 also showed a 
smaller but statistically significant increase in the particle size 
when compared with PLA25-PEG5 (P?0.01). These observa-
tions indicate that PLA forms the core of the nanoparticles that 
increases in size with increase in PLA chain length.28
Composite nanoparticles prepared with similar PLA 
molecular weight but longer PEG chains produced a smaller 
particle size, for example, PLA25-PEG5 ? PLA20-PEG2 
(P?0.001). We suggest that the increased amphiphilicity 
conferred by the longer chain length stabilizes the globules 
during emulsification. This in turn helps to produce uniform 
and smaller nanoparticles by avoiding coalescence.
All nanoparticles exhibited encapsulation efficiency ?60% 
except PLA10-PEG5 as described earlier. Further, PLA20-PEG2 
and PLA25-PEG5 produced nanoparticles with exceptionally 
high entrapment efficiency, which is attributed to the similar 
PLA chain length used in their formation that helped to pro-
duce a stable o/w/o emulsion enabling maximum engulfment 
of the RNPs. The negative zeta potential exhibited by all 
the composite nanoparticles indicates that all the positively 
charged RNPs were encapsulated into the core. On the basis 
of these results, PLA20-PEG2, PLA25-PEG5, and PLA50-PEG5 
were selected for further studies, with PLA25-PEG5 consid-
ered the best formulation because of its small size and high 
encapsulation efficiency.
Thermal properties of the composite 
nanoparticles
All products exhibited a Tg at 120?C, indicating that the treha-
lose was present in the amorphous state (Figure 3A),41 which 
Table 2 Physicochemical properties of the composite nanoparticles
Polymersa Z-average diameter (nm) PDI Zeta potential (mV) % entrapment efficiency
PLA10-PEG2 144.6?8.8 0.188?0.049 ?27.6?2.2 66.72?3.61
PLA20-PEG2 195.1?9.2 0.115?0.021 ?31.8?1.7 78.00?2.99
PLA10-PEG5 144.3?3.6 0.174?0.010 ?20.3?2.6 29.70?19.3
PLA25-PEG5 173.6?6.4 0.121?0.018 ?31.9?1.1 80.93?2.49
PLA50-PEG5 189.4?4.8 0.061?0.011 ?33.7?1.8 63.40?3.19
Notes: aSubscript shows molecular weight in kilodaltons. Results are shown as mean ? SD (n?6).
Abbreviations: PDI, polydispersity index; PLA, polylactic acid; PEG, polyethylene glycol; SD, standard deviation.
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Figure 3 Thermal transitions of the bulk copolymers and nanoparticles.
Note: MTDSC curves showing Tg regions of the composite nanoparticles prepared with copolymers as indicated (A) and Tg regions of the bulk copolymers (B).
Abbreviations: MTDSC, modulated temperature differential scanning calorimetry; PLA, polylactic acid; PEG, polyethylene glycol.
is desirable since crystallization of protectants in nanoparticle 
formulations has been shown to cause instability.42 The 
Tg values of composite nanoparticles were found to be 
higher than those of their respective copolymers (Figure 3B), 
which was attributed to the more confined architecture of the 
polymer chains within the composite nanoparticles than in the 
bulk polymer.43,44 A relatively small Tg increase was seen for 
the Tg value of PLA20-PEG2 nanoparticles compared with the 
bulk polymer indicating that other factors are also involved 
in determining the value of Tg, which could be interesting to 
explore in future studies.
The Tg values of the nanoparticles were found to be 
unaffected by the overall molecular weight of the polymer 
as exemplified by the similar values of PLA25-PEG5 and 
PLA50-PEG5 (Figure 3A). The PEG molecular weight 
had a greater plasticizing effect on Tg values than the 
PEG content. For example, PLA25-PEG5 and PLA50-PEG5 
exhibited similar Tg values and contained 18 mol% and 
8 mol% PEG, respectively. All the formulations exhibited 
a Tg value ?38?C indicating their structural stability at 
room temperature.
In-process stability study
Figure 4 shows representative images of the three different 
kinds of experiments performed to assess stability of the 
RNPs and the pDNA condensed in it during the formula-
tion of composite nanoparticles by double emulsion solvent 
evaporation method.
Gel electrophoresis was used to analyze the effect 
of probe sonication on the stability of the RNPs and the 
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entrapped DNA (Figure 4A). No DNA band was observed in 
the control lane D, which contained pDNA alone sonicated 
at 40% for 30 seconds. A faint DNA smear at the bottom 
of the lane shows that sonication degraded the DNA. In the 
lanes containing RNPs, no DNA was observed, indicating 
that it remained inside the RNPs during sonication. Sonicated 
RNPs predigested with proteinase K before loading to the 
gel released the DNA to migrate into the gel confirming that 
the DNA was stable inside the RNPs.
Data presented in Figure 4B indicate that both free DNA 
and RNPs are stable when vortexed with DCM. Samples 
digested with proteinase K exhibited DNA bands at the 
expected height confirming stability of DNA inside RNPs, 
whereas undigested samples did not show any fluorescence 
in the lane indicating the stability of RNPs with DCM. The 
data presented in Figure 4C show that the RNPs remained 
stable during the complete double emulsification process and 
also protected the encapsulated DNA from the shear stress 
posed by DCM and sonications.
Transmission electron microscopy
A new approach was developed whereby the hydrophobic 
dye osmium tetroxide was added to the polymeric organic 
phase during the preparation of the composite nanoparticles. 
The dye becomes molecularly dispersed in the polymer 
matrix only, giving a contrast background to the RNPs 
that makes them visible inside the composite nanoparticles 
(Figure 5). To our knowledge, this is the first time that this 
preparation method has been reported. The images show 
that the RNPs were spherical and ?50 nm (Figure 5A). 
RNPs are the bright areas in the center of the composite 
nanoparticles. These images give visual confirmation of RNP 
encapsulation inside the composite nanoparticles. Depending 
on the size, single or multiple RNPs are encapsulated within 
the composite nanoparticles.
In vitro release study
All the composite nanoparticles exhibited an initial burst 
release that accounted for the 8%–10% DNA released in 
first 24 hours, which is good for the priming of a therapeutic 
response (Figure 6). Four to five percent of this was DNA 
that had been released during freeze-drying as determined by 
centrifugation. The PLAx-PEG5 copolymers exhibited a larger 
burst release than PLA20-PEG2, which could be attributed to 
the longer PEG chains of the PLAx-PEG5 formulations since 
it is known that higher contact area with water enhances 
degradation rate.45 PLA25-PEG5 showed the highest amount 
of DNA release at every time point, which was attributed to 
a number of factors, longer PEG chains, shorter PLA chains, 
and the low Tg, which was closest to the temperature of the 
release medium. The longer PEG chains might have caused 
a higher degradation rate in this system, and increased PEG 
content has been correlated with increase in cargo release.46 
The other two formulations have a higher ratio of PLA 
chain length to PEG, which slows the degradation profile. 
All three composite nanoparticles were deemed acceptable. 
The PLA25-PEG5 was taken forward for the transfection study 
because of its higher release rate.
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Figure 7 In vitro transfection of ZR-75-1 cell lines with PLA25-PEG5 composite nanoparticles and transferrin-modified PLA25-PEG5 composite nanoparticles (Tf-composites).
Notes: (A) Particle size and zeta potential characterization of RNPs, composite nanoparticles, and Tf-composite nanoparticles; (B) percent cell viability after treatment of 
the ZR-75-1 cells with nanoparticles; (C) transfection efficiency by flow cytometry and fluorescent microscopy: (i) DNA only; (ii) RNPs; (iii) composite nanoparticles; and 
(iv) Tf-composites. The top row depicts the bright field images, and the bottom row shows the same samples under fluorescence. Magnification was ?100. The numbers on 
the images indicate the percentage of cells expressing the GFP determined by flow cytometry.
Abbreviations: PLA, polylactic acid; PEG, polyethylene glycol; RNPs, RALA nanoparticles; GFP, green fluorescent protein; PDI, polydispersity index.
These data also demonstrate the stability of the released 
DNA over the time course of the study since the PicoGreen 
reagent binds specifically to the double-stranded DNA; 
therefore, the concentrations are of stable double-stranded 
DNAs only.
In vitro transfection and cell viability 
study
In vitro transfection studies were performed to evaluate the 
transfection efficiency of composite nanoparticles manufac-
tured with PLA25-PEG5. Transferrin-appended PLA25-PEG5 
composite nanoparticles were also studied as previous reports 
have shown that transferrin-adsorbed nanoparticles can 
exhibit enhance cellular uptake with good stability in vivo.31 
Transfection was compared with un-encapsulated RNPs. 
Figure 7A shows the particle size and zeta potential data 
obtained for the nanoparticles used in the study and indicate 
that transferrin adsorption caused a large increase in zeta 
potential, confirming the adsorption of the transferrin on 
the surface of composite nanoparticles. In the current study, 
transferrin-adsorbed nanoparticles were collected by high-
speed centrifugation and vigorous vortexing; the presence of 
transferrin on the surface of the nanoparticles even after these 
shear forces indicates their physical stability of the system.
The cell viability assay indicated that the nanoparticles 
were all nontoxic (Figure 7B). The RNPs exhibited 68% 
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transfection, and expression of the green fluorescent protein 
was analyzed by flow cytometry (Figure 7C), which is in line 
with our previous findings,19 and confirmed the suitability of 
using these RNPs for efficient translocation of the DNA into 
the cells. In contrast, composite nanoparticles showed a much 
lower expression. Transferrin-appended composite nanopar-
ticles exhibited a significantly (P?0.05) higher fluorescence 
that could be attributed to transferrin receptor-mediated 
uptake.30,47,48 These results indicate that RNPs are superior over 
composite nanoparticles over the 24-hour period of the study, 
even with the additional advantage conferred by Tf-conjuga-
tion. This apparent low-transection efficiency is attributed to 
the slow release of the RNPs from composite nanoparticles 
and could be advantageous in the in vivo setup.
Conclusion
This study has successfully demonstrated the manufac-
ture of composite nanoparticle systems based on cationic 
peptide-DNA nanoparticles (RNPs) encapsulated within a 
PLA-PEG nanoparticle. Formulation of RNPs was studied 
at various N:P ratios in order to obtain a reproducible 
Z-average diameter ?100 nm. RNPs were further optimized 
with more stringent conditions such as type of buffer, buffer 
capacity, ionic strength, buffer pH, and microenvironment 
to control this electrostatic interaction and obtain RNPs, 
with the suitable characteristics required for formulation of 
composite NPs. Finally, RNPs of 55 nm (Z-average diameter) 
were prepared in 50 mM MOPS buffer at 50?C with DNA 
concentration of 400 ?g/mL and were shown to be stable 
during the emulsification-based encapsulation process. For 
the second component, various compositions of PLA-PEG 
block copolymers were explored. On the basis of the ther-
mal characterization of the copolymers and their efficiency 
to encapsulate RNPs, three copolymers were selected for 
the further studies, such as PLA20-PEG2, PLA25-PEG5, 
and PLA50-PEG5. Composite nanoparticles based on these 
copolymers exhibited a range of acceptable DNA release 
rates over a 6-week in vitro study. The continuous slow 
release indicates that these systems might be able to exhibit 
prolonged delivery of DNA after administration that could 
avoid the requirement for frequent dosing, which is known 
to enhance patient compliance, while a transfection study 
showed their ability to transfect cells without compromis-
ing cell viability. It is beyond the scope of the short in vitro 
transfection study to show the impact of controlled release 
over a longer time period to evaluate the efficacy of the 
composite nanoparticles as a whole system. A dedicated 
in vivo gene delivery study would be useful to further explore 
the potential of this new type of composite nanoparticle 
system. Thus, this study has shown the potential to design 
composite nanoparticles for prolonged and safe gene delivery 
and demonstrates that such systems are promising candidates 
for effective gene therapy.
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Figure S1 MTDSC analysis of the PLA-PEG copolymers synthesized for preparation of the composite nanoparticles for the determination of Tm.
Abbreviations: MTDSC, modulated temperature differential scanning calorimetry; PLA, polylactic acid; PEG, polyethylene glycol.
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Figure S2 Effect of DNA/polymer ratio on the size and zeta potential of composite nanoparticles.
Note: Data are shown as mean ? SD (n?3).
Abbreviations: SD, standard deviation; RNPs, RALA nanoparticles.
